Last reviewed · How we verify

Short duration of aspirin and prasugrel

Odense University Hospital · FDA-approved active Small molecule Quality 0/100

Short duration of aspirin and prasugrel is a Small molecule drug developed by Odense University Hospital. It is currently FDA-approved.

At a glance

Generic nameShort duration of aspirin and prasugrel
SponsorOdense University Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Short duration of aspirin and prasugrel

What is Short duration of aspirin and prasugrel?

Short duration of aspirin and prasugrel is a Small molecule drug developed by Odense University Hospital.

Who makes Short duration of aspirin and prasugrel?

Short duration of aspirin and prasugrel is developed and marketed by Odense University Hospital (see full Odense University Hospital pipeline at /company/odense-university-hospital).

What development phase is Short duration of aspirin and prasugrel in?

Short duration of aspirin and prasugrel is FDA-approved (marketed).

Related